Novartis vets Jimenez, Fishman thread digital into fabric of new VC firm Aditum, launch Tempero 

With two spinouts and a partnership with software company TrialSpark, Aditum sets path to incorporate digital apps in portfolio companies from the get-go

November 4, 2020 12:08 AM UTC

Novartis’ former CEO Joe Jimenez and NIBR head Mark Fishman believe that pairing digital technology with drug development in large underserved indications can provide a solid investment model and expedite the creation of medicines in disease areas that have been all but abandoned by their former peer pharma companies.

Together with co-founder Paul Sekhri, president and CEO of eGenesis Inc., they created investment firm Aditum Bio in 2019. Sekhri — a veteran executive of Novartis AG (NYSE:NVS; SIX:NOVN) himself  — is remaining at eGenesis.  ...